Tumor Model Development Service

Tumor models are indispensable translational tools for evaluating the biodistribution, targeting specificity, and therapeutic efficacy of radioconjugate drug candidates. Alfa Cytology offers fully customized tumor model development services, from model selection and engineering to in vivo characterization, designed to align with your RDC's mechanism of action, target expression profile, and intended indication. Every model is developed under rigorous quality control and with predictive relevance, ensuring that your preclinical data robustly inform IND‑enabling studies.

Overview of Tumor Models in RDC Development

In radioconjugate drug development, the choice of tumor model directly influences the interpretation of key pharmacokinetic and pharmacodynamic endpoints. Unlike conventional small‑molecule or biologic agents, RDCs require models that not only recapitulate human tumor biology but also accommodate the unique constraints of radiolabeling, such as stable target density over time, accessible vascularity, and manageable radiation dose burden to host tissues. A well‑designed tumor model enables accurate assessment of tumor uptake, residence time, normal organ clearance, and therapeutic window.

Fig.1 Preclinical biodistribution and therapy response of ¹⁷⁷Lu-rhPSMA-10.1 in prostate cancer. (Foxton, C., et al., 2025)

Classification of Tumor Models in RDC Development

Our Services

Leveraging extensive experience in radiopharmaceutical preclinical development, we provide end‑to‑end customization of tumor models that goes beyond standard xenografting. Alfa Cytology's capabilities encompass tailor‑made model engineering, including inducible target expression, reporter gene co‑expression for optical or nuclear imaging, and immune‑humanized platforms, to match your RDC's unique binding epitope and affinity. We also adapt model parameters, such as tumor size at study initiation, implantation site, co‑administration of unlabeled competitors, and dosing schedules, to mimic proposed clinical regimens. All models are validated through rigorous baseline characterization of target density, proliferation index, and perfusion status, ensuring that your RDC is tested under the most physiologically and clinically relevant conditions.

Workflow of Tumor Model Development for RDC Research

• Model Selection & Feasibility Assessment: Reviewing your target biology, antibody/ligand properties, and desired endpoints to recommend the most appropriate model class and host strain.
• Model Engineering or Acquisition: Generating or sourcing validated cell lines, patient tumor fragments, or genetically modified animals, complete with full documentation of passage history and genotypic/phenotypic stability.
• Baseline Characterization: Performing quantitative target expression analysis (via flow cytometry, IHC, or radioligand binding assays), growth kinetics, and spontaneous metastasis profiling to establish baseline reference parameters.
• Study Design & Dose Optimization: Defining the optimal implantation site, cell inoculation density, tumor growth window, and test article dosing regimens, including cold-competition and blocking groups to assess target specificity.
• In Vivo Pilot Run: Conducting small-scale biodistribution and imaging studies using surrogate radiotracers to confirm target accessibility, estimate tumor uptake kinetics, and refine dosimetry calculations.
• Full-Scale Preclinical Evaluation: Executing definitive efficacy, safety, and dosimetry studies with integrated PK/PD sampling and longitudinal histopathological confirmation at study termination.
• Data Analysis & Validation: Compiling imaging datasets, ex vivo gamma counting, and histopathology data into a comprehensive model performance report designed to seamlessly support international IND filings.

Comprehensive Portfolio of Available Tumor Models

Alfa Cytology offers development services across a broad spectrum of tumor models, including CDX, PDX, syngeneic models, and humanized immune‑system platforms. Each model can be established from scratch or adapted from characterized starting materials, with customization options for orthotopic implantation, metastatic dissemination, and combination study designs. Our capabilities are fully flexible to support radioconjugate development, enabling tailored biodistribution, imaging, and efficacy assessments aligned with specific program needs.

• Cell Line Xenograft (CDX) Models

Available host strains: Nude, SCID, NOD-SCID, NOG/NSG, and NRG immunodeficient mice.

• Patient-Derived Xenograft (PDX) Models

Available host strains: Nude, SCID, NOD-SCID, NOG/NSG, and NRG immunodeficient mice.

• Syngeneic Models

• Humanized Mouse Models

Why Choose Us?

• Scientific Expertise: A multidisciplinary team spanning tumor biology, radiochemistry, and nuclear imaging, with practical knowledge of radioligand physics and biology to ensure model alignment with nuclear medicine requirements.
• Customized Solutions: Designing bespoke solutions around your specific target profile and chosen isotopes, allowing for customized target engineering, unique inoculation sites, and adaptive imaging windows tailored to individual candidate pharmacokinetics.
• Integrated One-Stop Services: Providing a truly end-to-end preclinical pipeline that bridges initial target cell line development, animal modeling, radiolabeling, in vitro/in vivo binding analysis, biodistribution profiling, and micro-imaging under one unified roof.
• High-Quality Data: Delivering meticulously quantified, reproducible datasets, backed by stringent quality control and comprehensive documentation designed to smoothly support international IND-enabling regulatory filings.

Contact Us

Alfa Cytology's tumor model development service delivers scientifically rigorous, fit‑for‑purpose preclinical models that accelerate your RDC program from target validation to candidate selection and IND-enabling studies. We combine flexible model design with rigorous analytical support, ensuring that every dataset you generate is robust, interpretable, and translatable. To discuss your specific model requirements or to request a customized proposal, please reach out to our scientific team. We are ready to partner with you at any stage of your development journey.

For research use only. Not intended for any clinical use.